HRP20040619A2 - Combination of cytochome p<sub>450</sub> dependent protease inhibitors - Google Patents

Combination of cytochome p<sub>450</sub> dependent protease inhibitors Download PDF

Info

Publication number
HRP20040619A2
HRP20040619A2 HR20040619A HRP20040619A HRP20040619A2 HR P20040619 A2 HRP20040619 A2 HR P20040619A2 HR 20040619 A HR20040619 A HR 20040619A HR P20040619 A HRP20040619 A HR P20040619A HR P20040619 A2 HRP20040619 A2 HR P20040619A2
Authority
HR
Croatia
Prior art keywords
het1
het2
alkyl
aryl
cycloalkyl
Prior art date
Application number
HR20040619A
Other languages
English (en)
Croatian (hr)
Inventor
Van Der Geest Ronald
Stoffels Paul
Groen Cornelis
Edward Desire Jochmans Dirk
Original Assignee
Tibotec Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20040619(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceuticals Ltd. filed Critical Tibotec Pharmaceuticals Ltd.
Publication of HRP20040619A2 publication Critical patent/HRP20040619A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
HR20040619A 2001-12-12 2002-12-12 Combination of cytochome p<sub>450</sub> dependent protease inhibitors HRP20040619A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204841 2001-12-12
PCT/EP2002/014277 WO2003049746A2 (fr) 2001-12-12 2002-12-12 Combinaison d'inhibiteurs de protease dependant du cytochrome p450

Publications (1)

Publication Number Publication Date
HRP20040619A2 true HRP20040619A2 (en) 2005-08-31

Family

ID=8181408

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040619A HRP20040619A2 (en) 2001-12-12 2002-12-12 Combination of cytochome p<sub>450</sub> dependent protease inhibitors

Country Status (27)

Country Link
US (1) US20050119338A1 (fr)
EP (1) EP1458447B1 (fr)
JP (1) JP2005511723A (fr)
KR (1) KR100974921B1 (fr)
CN (1) CN100335060C (fr)
AR (1) AR037797A1 (fr)
AT (1) ATE442189T1 (fr)
AU (1) AU2002358713B2 (fr)
BR (1) BR0215043A (fr)
CA (1) CA2469343C (fr)
CY (1) CY1110604T1 (fr)
DE (1) DE60233677D1 (fr)
DK (1) DK1458447T3 (fr)
ES (1) ES2333206T3 (fr)
HR (1) HRP20040619A2 (fr)
HU (1) HUP0402644A3 (fr)
IL (1) IL162353A0 (fr)
MX (1) MXPA04005755A (fr)
NO (1) NO20042666L (fr)
NZ (1) NZ533826A (fr)
PL (1) PL373072A1 (fr)
PT (1) PT1458447E (fr)
RU (1) RU2329050C2 (fr)
SI (1) SI1458447T1 (fr)
TW (1) TWI286476B (fr)
WO (1) WO2003049746A2 (fr)
ZA (1) ZA200404633B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4919802B2 (ja) * 2003-09-30 2012-04-18 テイボテク・フアーマシユーチカルズ ベンゾオキサゾールスルホンアミド化合物およびその中間体の製造方法
AU2004308712A1 (en) * 2003-12-23 2005-07-14 Tibotec Pharmaceuticals Ltd. Self-microemulsifying drug delivery systems of a HIV protease inhibitor
EP2422781A1 (fr) * 2004-05-07 2012-02-29 Sequoia Pharmaceuticals, Inc. Inhibiteurs de la protéase rétrovirale résistants/répulsifs
JP2008505870A (ja) * 2004-07-08 2008-02-28 テイボテク・フアーマシユーチカルズ・リミテツド 抗ｈｉｖ逆転写酵素およびプロテアーゼ阻害剤の組合せ剤
RU2421459C2 (ru) 2005-02-25 2011-06-20 Тиботек Фармасьютикалз Лтд. Синтез предшественника ингибитора протеазы
JP2008538354A (ja) * 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
AR053845A1 (es) * 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
TWI385173B (zh) * 2005-11-28 2013-02-11 Tibotec Pharm Ltd 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物
TWI432438B (zh) * 2005-11-28 2014-04-01 Tibotec Pharm Ltd 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物及衍生物
JP4676536B2 (ja) * 2005-12-30 2011-04-27 ギリアド サイエンシズ， インコーポレイテッド Ｈｉｖインテグラーゼ阻害剤の薬物動態の改善方法
JO2841B1 (en) 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
US8048871B2 (en) * 2006-08-18 2011-11-01 Sequoia Pharmaceuticals, Inc. Compositions and methods for inhibiting cytochrome P450
CA2681718A1 (fr) * 2007-03-23 2008-10-02 University Of Massachusetts Inhibiteurs de la protease du vih-1
UA103013C2 (uk) 2007-12-06 2013-09-10 Тиботек Фармасьютикелз Амідні сполуки як активатори противірусних препаратів
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
EP2254582B1 (fr) 2008-01-25 2016-01-20 Chimerix, Inc. Méthodes de traitement d'infections virales
BRPI0920809A2 (pt) 2008-10-07 2016-07-12 Tibotec Pharm Ltd compostos de amida como reforcos de antivirais
EP2429290B1 (fr) * 2009-05-11 2014-01-01 Purdue Research Foundation Composés et méthodes utilisables dans le cadre du traitement du sida et des infections par le vih
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
CN102985420B (zh) * 2010-06-01 2017-07-04 安吉翁生物医药有限公司 细胞色素p450抑制剂及其用途
LT2729130T (lt) 2011-07-07 2018-01-10 Janssen Sciences Ireland Uc Darunaviro derinių kompozicijos
PT2729128T (pt) 2011-07-07 2016-09-21 Janssen Sciences Ireland Uc Formulações de darunavir

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7973994A (en) * 1993-10-13 1995-05-04 Merck & Co., Inc. Combination therapy for hiv infection
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
NZ334227A (en) * 1996-08-05 2000-10-27 Molecumetics Ltd Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
US6180634B1 (en) * 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
PT2336134T (pt) * 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
WO1999067254A2 (fr) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Inhibiteurs de protease retrovirale resistant a l'action de plusieurs medicaments et procedes associes
CO5090830A1 (es) * 1998-07-20 2001-10-30 Abbott Lab Poliformo de un agente farmaceutico
ES2254156T3 (es) * 1999-02-12 2006-06-16 Vertex Pharmaceuticals Incorporated Inhibidores de aspartil-proteasa.
TWI260322B (en) * 1999-02-12 2006-08-21 Vertex Pharma Inhibitors of aspartyl protease

Also Published As

Publication number Publication date
CA2469343A1 (fr) 2003-06-19
RU2329050C2 (ru) 2008-07-20
CY1110604T1 (el) 2015-04-29
AU2002358713B2 (en) 2009-01-29
KR100974921B1 (ko) 2010-08-09
RU2004121144A (ru) 2005-04-20
NO20042666L (no) 2004-09-09
ZA200404633B (en) 2005-09-01
DK1458447T3 (da) 2010-01-18
HUP0402644A3 (en) 2008-04-28
CN1604803A (zh) 2005-04-06
NZ533826A (en) 2006-04-28
PT1458447E (pt) 2009-12-16
AR037797A1 (es) 2004-12-01
KR20040071182A (ko) 2004-08-11
WO2003049746A2 (fr) 2003-06-19
HUP0402644A2 (en) 2007-02-28
DE60233677D1 (de) 2009-10-22
MXPA04005755A (es) 2004-09-10
PL373072A1 (en) 2005-08-08
SI1458447T1 (sl) 2010-01-29
CN100335060C (zh) 2007-09-05
AU2002358713A1 (en) 2003-06-23
TW200409624A (en) 2004-06-16
IL162353A0 (en) 2005-11-20
JP2005511723A (ja) 2005-04-28
TWI286476B (en) 2007-09-11
WO2003049746A3 (fr) 2003-12-31
CA2469343C (fr) 2008-05-13
ES2333206T3 (es) 2010-02-18
BR0215043A (pt) 2004-11-03
EP1458447B1 (fr) 2009-09-09
EP1458447A2 (fr) 2004-09-22
HK1070008A1 (en) 2005-06-10
ATE442189T1 (de) 2009-09-15
US20050119338A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
HRP20040619A2 (en) Combination of cytochome p&lt;sub&gt;450&lt;/sub&gt; dependent protease inhibitors
CA3139977A1 (fr) Peptidomimetiques pour le traitement d&#39;infections par coronavirus et picornavirus
JP5940586B2 (ja) シトクロムｐ４５０を阻害するための組成物および方法
EP1986633A2 (fr) Traitement de la dystrophie musculaire de duchenne
TWI780329B (zh) 經1,3-噻唑-2-基取代之苯甲醯胺用於治療與神經纖維敏化作用相關疾病之用途
CA2440374A1 (fr) Composition pharmaceutique pour le traitement de la depression comprenant un antagoniste ep1 en tant que principe actif
HUE027171T2 (en) 1-Phenyl-2-pyridinylalkyl alcohol derivatives as phosphodiesterase inhibitors
KR20090114389A (ko) 무스카린성 수용체 길항제와 베타-2-아드레날린성 수용체 효능제의 조합물
KR20220152293A (ko) Covid-19 관련 병태의 치료 방법
CN117529320A (zh) 用于治疗病毒感染的rock2抑制剂
TW200817416A (en) 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
JPWO2001072723A1 (ja) オキサ（チア）ゾリジン誘導体および抗炎症薬
EA008594B1 (ru) 2-аминобензотиазолсульфонамидные ингибиторы протеазы вич широкого спектра действия
EA010911B1 (ru) Ингибиторы проникновения вируса вич
JPWO2021147974A5 (fr)
KR20230118855A (ko) IRE1α 억제제 및 이의 용도
JPH0653678B2 (ja) アレルギ−性疾患治療剤
HK1070008B (en) Combination of cytochome p 450 dependent protease inhibitors
HK40090264A (zh) 用於治疗covid-19相关病症的方法
EA049122B1 (ru) Способ лечения связанных с covid-19 состояний
CN120548182A (zh) 用于治疗病毒感染的rock2抑制剂
JPH0449236A (ja) ニカルジピン含有ホスホリパーゼａ↓２阻害剤
JP2006511483A (ja) ２’’オキソ−ボルウスカリンおよびその誘導体
JP2006076947A (ja) ホスホリパーゼａ（２）の活性亢進を伴う疾患用薬

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20101209

Year of fee payment: 9

OBST Application withdrawn